Impact of Genetics and Cannabis on Psychosis Risk
Author Information
Author(s): Austin-Zimmerman Isabelle, Spinazzola Edoardo, Quattrone Diego, Wu-Choi Beatrice, Trotta Giulia, Li Zhikun, Johnson Emma, Richards Alexander L., Freeman Tom P., Tripoli Giada, Gayer-Anderson Charlotte, Rodriguez Victoria, Jongsma Hannah E., Ferraro Laura, La Cascia Caterina, Tosato Sarah, Tarricone Ilaria, Berardi Domenico, Bonora Elena, Seri Marco, D'Andrea Giuseppe, Szöke Andrei, Arango Celso, Bobes Julio, Sanjuán Julio, Santos Jose Luis, Arrojo Manuel, Velthorst Eva, Bernardo Miguel, Del-Ben Cristina Marta, Rossi Menezes Paulo, Selten Jean-Paul, Jones Peter B., Kirkbride James B., Rutten Bart P. F., Tortelli Andrea, Llorca Pierre-Michel, de Haan Lieuwe, Stilo Simona, La Barbera Daniele, Lasalvia Antonio, Schurnhoff Franck, Pignon Baptiste, van Os Jim, Lynskey Michael, Morgan Craig, EU-GEI WP2 Group, O’ Donovan Michael, Lewis Cathryn M., Sham Pak C., Murray Robin M., Vassos Evangelos, Di Forti Marta
Primary Institution: King's College London
Hypothesis
What is the independent and combined effect of heavy cannabis use and schizophrenia polygenic risk score on the risk for psychotic disorder?
Conclusion
Regular use of high-potency cannabis is a strong predictor of psychotic disorder, independent of genetic risk for schizophrenia.
Supporting Evidence
- Schizophrenia PRS and cannabis use independently increased risk of psychosis.
- Regular users of high-potency cannabis had the highest odds of being a case.
- Schizophrenia PRS was not associated with patterns of cannabis use in the EU-GEI cases or controls.
- Daily cannabis use significantly increased the odds of psychosis.
- Adding CUD PRS did not improve the model fit for schizophrenia PRS.
Takeaway
Using strong cannabis can make you more likely to have serious mental health problems, even if your family doesn't have a history of these issues.
Methodology
Data from the EU-GEI case-control study and UK Biobank were analyzed to assess the effects of cannabis use and genetic risk on psychosis.
Potential Biases
Participants were predominantly of European ancestry, which may limit the generalizability of the findings.
Limitations
The study relies on self-reported cannabis use, which may not accurately reflect actual use patterns.
Participant Demographics
The study included first-episode psychosis patients and population controls from various European countries.
Statistical Information
P-Value
3.21 × 10−10
Confidence Interval
95% CI 3.08–8.43
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website